Literature DB >> 2759328

Biliverdin reductase activity in cattle, sheep, rabbits and rats.

J W George1, K Nulk, A Weiss, M L Bruss, C E Cornelius.   

Abstract

1. Biliverdin reductase (BVR) activity was measured in post-microsomal supernatants of livers of cattle, sheep, rabbits and rats. BVR activities in bovine and ovine livers were 4.7 and 5.0%, respectively, of rat liver activity. 2. The finding of BVR activity in ruminants is in contrast to a previous report and may be due to the use of a different assay system. 3. Lapine liver had the lowest BVR activity of only 0.37% of rat liver activity. 4. Increasing the available heme by phenylhydrazine administration did not induce increased hepatic or splenic BVR activity in rabbits. 5. Maximal BVR activities were attained using NADPH as cofactor at pH 8.7 in sheep and rabbits and at pH 8.4 in cattle. 6. Differing concentrations of bovine or human albumins enhanced or inhibited BVR activity quite differently in the various species. 7. The finding of a very low, but measurable BVR activity in lapine liver and spleen may explain, in part, why rabbits, unlike rats, cattle and sheep, excrete primarily biliverdin (70%) into bile.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2759328     DOI: 10.1016/0020-711x(89)90127-4

Source DB:  PubMed          Journal:  Int J Biochem        ISSN: 0020-711X


  3 in total

1.  Inactivation of digestive proteases by deconjugated bilirubin: the possible evolutionary driving force for bilirubin or biliverdin predominance in animals.

Authors:  Xiaofa Qin
Journal:  Gut       Date:  2007-11       Impact factor: 23.059

2.  A protective role for heme oxygenase-1 in INS-1 cells and rat islets that are exposed to high glucose conditions.

Authors:  Kyu Chang Won; Jun Sung Moon; Mi Jung Eun; Ji Sung Yoon; Kyung Ah Chun; Ihn Ho Cho; Yong Woon Kim; Hyoung Woo Lee
Journal:  J Korean Med Sci       Date:  2006-06       Impact factor: 2.153

Review 3.  Biliverdin reductase: a target for cancer therapy?

Authors:  Peter E M Gibbs; Tihomir Miralem; Mahin D Maines
Journal:  Front Pharmacol       Date:  2015-06-03       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.